CXCL11

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

Retrieved on: 
Wednesday, April 10, 2024
PFS, University, Epithelium, UPMC Magee-Womens Hospital, Pancreatic cancer, Triple-negative breast cancer, Colorectal cancer, Research, Cisplatin, AIM, MD, Peritoneum, Gynecologic Oncology (journal), UPMC, Gynaecology, Disease, Liver, Patient, CXCL10, CXCL11, Reproductive Sciences, Progression-free survival, Data analysis, Neoplasm, Biomarker, CXCL9, Cancer, RNA, Ovarian cancer, Medical imaging

See further details on the study “Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer” at ClinicalTrials.gov: NCT03734692 .

Key Points: 
  • See further details on the study “Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer” at ClinicalTrials.gov: NCT03734692 .
  • Additionally, the immunological signature supporting this synergistic enhancement has been seen in other clinical trials, including with pancreatic cancer ( 1 , 2 ) metastatic triple-negative breast cancer and colorectal cancer metastatic to the liver .
  • Ampligen is a dsRNA product candidate that acts via the TLR-3 receptor present on several immune cells, epithelial cells and most solid tumors.
  • Additionally, Keynote-100’s median PFS was 2.1 months, or significantly less than that seen in the ongoing Ampligen study.

Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update

Retrieved on: 
Thursday, March 28, 2024
HCC, Research, Epigenomics, Toxicity, Obesity, Cell death, Growth, Burns, Gene expression, Novo Nordisk, NSCLC, AASLD, Appetite, OMEGA, DCR, Patient, Lung, Tissue, Cohort, CXCL9, CXCL10, Omega, G&A, Cancer, Messenger, Lung cancer, Human, Life expectancy, Liver regeneration, DLT, Fibrosis, Thermogenesis, Therapy, MYC, Liver, Pharmacokinetics, Hepatitis, CXCL11, LNP, Pharmaceutical industry

Research and development (R&D) expenses for the fourth quarter of 2023 were $15.5 million, compared to $26.0 million for the fourth quarter of 2022.

Key Points: 
  • Research and development (R&D) expenses for the fourth quarter of 2023 were $15.5 million, compared to $26.0 million for the fourth quarter of 2022.
  • General and administrative (G&A) expenses for the fourth quarter of 2023 were $6.2 million, compared to $5.7 million for the fourth quarter of 2022.
  • Net loss for the fourth quarter of 2023 was $20.2 million, compared to $30.8 million for the fourth quarter of 2022.
  • The decrease in net loss for 2023 compared to 2022 was primarily due to decreases in R&D expenses.

Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis

Retrieved on: 
Monday, November 13, 2023
Therapy, CXCL10, CXCL11, Cirrhosis, AASLD, ECS, Mouse, CXCL9, Liver, Gene expression, Messenger, Hepatocyte, FRG, Chemokine, Cell, Inflammation, Fibrosis, Vaccine, Boston

CAMBRIDGE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the presentation of new preclinical data from two different programs that demonstrated sustained upregulation of gene expression and coordinated pre-transcriptional downregulation of multiple genes in models of liver fibrosis and inflammation, respectively, at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2023, taking place in Boston, Massachusetts, November 10 – 14.

Key Points: 
  • However, to extend their reach, we need to bidirectionally control the expression of multiple genes simultaneously,” said Thomas McCauley, Ph.D., Chief Scientific Officer of Omega Therapeutics.
  • “We believe that these new data demonstrate the power of our programmable epigenomic mRNA development candidates to control gene expression with unmatched flexibility.
  • To our knowledge, these are the first results to show how site-specific epigenomic modulation can durably upregulate the expression of a master liver regeneration gene.
  • EC-mediated induction of HNF4α expression in vivo in a mouse model of liver fibrosis led to decreased collagen deposition, a key marker of fibrosis.

AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer

Retrieved on: 
Wednesday, November 8, 2023
MSD, Society for Immunotherapy of Cancer, Plasma, AIM, NYSE, Ovarian cancer, Biomarker, Therapy, Tumor necrosis factor, Viral, TNF, Pembrolizumab, DSM-IV codes, Cisplatin, PBMC, CXCL9, Research, CXCR3, University of Pittsburgh School of Medicine, Function (mathematics), SITC, Immunotherapy, CXCL11, Perforin-1, Cancer, Annual general meeting, University, Tumor microenvironment, CXCL10, Wilfrid Sellars, TME, IP, Patient, UPMC, Pharmaceutical industry, Merck

OCALA, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today announced encouraging translational data from an ongoing Phase 2 clinical trial utilizing AIM’s drug Ampligen® in patients with platinum-sensitive advanced recurrent ovarian cancer.

Key Points: 
  • The data was also made available at the conference in a poster presentation .
  • Sequential sampling of the IP cavity showed an increase in cellularity immediately after treatment consistent with an “acute” pro-inflammatory reaction.
  • These data show a similar profile to previously published data from Roswell Park in Stage 4 triple negative breast cancer.
  • Additionally, we hope to announce topline interim survival results from UPMC in the near future.”
    For more information about the Phase 2 clinical trial of platinum-sensitive advanced recurrent ovarian cancer utilizing Ampligen®, visit clinicaltrials.gov and reference identifier: NCT03734692.

SIAF: Disrupted epithelial barriers as a predictor of severe COVID-19 development

Retrieved on: 
Monday, July 10, 2023
Permeability (electromagnetism), DNA, University of Zurich, Asthma, Obesity, Dysbiosis, University, TRANCE, Diabetes, AXIN1, Infection, COVID-19, CXCL10, End organ damage, Atopic dermatitis, Research, European Academy of Allergy and Clinical Immunology, Biomarker, Microbiota, Swiss Institute Contemporary Art New York, Journal, HIV disease progression rates, DSM-IV codes, Patient, Swiss Institute of Allergy and Asthma Research, AREG, Reading, Conditional sentence, CXCL11, Death, Allergen, Maharashtra University of Health Sciences, Autoimmunity, Rheumatoid arthritis, Inflammation, CLEC4C, Vaccine, Allergy

DAVOS, Switzerland, July 10, 2023 /PRNewswire/ -- According to the epithelial barrier theory, disruption of epithelial barriers by environmental and toxic agents triggers microbial dysbiosis, bacterial translocation to subepithelial areas and local or systemic immune/inflammatory response to environmental agents, allergens and microbes. Such events have been implicated in the development of chronic conditions like allergic, autoimmune, and metabolic diseases, such as diabetes, obesity, rheumatoid arthritis, allergies, asthma, atopic dermatitis. In severe cases of COVID-19, characteristic features include hyperinflammation, hyperactivated immune responses (referred to as the cytokine storm), cellular infiltration, and organ damage.

Key Points: 
  • In severe cases of COVID-19, characteristic features include hyperinflammation, hyperactivated immune responses (referred to as the cytokine storm), cellular infiltration, and organ damage.
  • The compromised epithelial barriers in the mucosas, particularly in gut mucosa facilitates the translocation of microbiota and their secreted metabolites, thus initiating or exacerbating inflammatory cascades in many inflammatory diseases.
  • The research group of epithelial biology in the Swiss Institute of Allergy and Asthma Research, associated with the University of Zurich, has been working on epithelial barriers for more than 20 years.
  • The authors analyzed the amount of bacterial DNA leakage to circulation and showed the link between disrupted epithelial barriers and an excessive inflammatory response.

SIAF: Disrupted epithelial barriers as a predictor of severe COVID-19 development

Retrieved on: 
Monday, July 10, 2023
Permeability (electromagnetism), DNA, University of Zurich, Asthma, Obesity, Dysbiosis, University, TRANCE, Diabetes, AXIN1, Infection, COVID-19, CXCL10, End organ damage, Atopic dermatitis, Research, European Academy of Allergy and Clinical Immunology, Biomarker, Microbiota, Swiss Institute Contemporary Art New York, Journal, HIV disease progression rates, DSM-IV codes, Patient, Swiss Institute of Allergy and Asthma Research, AREG, Reading, Conditional sentence, CXCL11, Death, Allergen, Maharashtra University of Health Sciences, Autoimmunity, Rheumatoid arthritis, Inflammation, CLEC4C, Vaccine, Allergy

DAVOS, Switzerland  , July 9, 2023 /PRNewswire/ -- According to the epithelial barrier theory, disruption of epithelial barriers by environmental and toxic agents triggers microbial dysbiosis, bacterial translocation to subepithelial areas and local or systemic immune/inflammatory response to environmental agents, allergens and microbes. Such events have been implicated in the development of chronic conditions like allergic, autoimmune, and metabolic diseases, such as diabetes, obesity, rheumatoid arthritis, allergies, asthma, atopic dermatitis. In severe cases of COVID-19, characteristic features include hyperinflammation, hyperactivated immune responses (referred to as the cytokine storm), cellular infiltration, and organ damage.

Key Points: 
  • In severe cases of COVID-19, characteristic features include hyperinflammation, hyperactivated immune responses (referred to as the cytokine storm), cellular infiltration, and organ damage.
  • The compromised epithelial barriers in the mucosas, particularly in gut mucosa facilitates the translocation of microbiota and their secreted metabolites, thus initiating or exacerbating inflammatory cascades in many inflammatory diseases.
  • The research group of epithelial biology in the Swiss Institute of Allergy and Asthma Research, associated with the University of Zurich, has been working on epithelial barriers for more than 20 years.
  • The authors analyzed the amount of bacterial DNA leakage to circulation and showed the link between disrupted epithelial barriers and an excessive inflammatory response.

Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma

Retrieved on: 
Friday, November 11, 2022
GTR, Form, Cytokine, Nivolumab, SITC, Content discovery platform, Company, Gamma ray, Biology, Prostate cancer, MD, Combination therapy, Private Securities Litigation Reform Act, Therapy, Cancer, HSV, Immunotherapy, GLOBE, Doctor of Philosophy, Patient, STR, SEC, CXCL11, Chemokine, CADL, Neoplasm, Tumor microenvironment, MOS, MGMT, Pancreatic cancer, Large-cell lung carcinoma, Immunogenic cell death, Nasdaq, Pharmaceutical industry, Vaccine, Fellow of the Academy of Medical Sciences, Candel

Data were presented at the 37th Annual Meeting of Society for Immunotherapy of Cancer (SITC) today in Boston.

Key Points: 
  • Data were presented at the 37th Annual Meeting of Society for Immunotherapy of Cancer (SITC) today in Boston.
  • Proteomic analysis by OLINK revealed an increase in pro-inflammatory cytokines, including interferon-gamma, the chemokines CXCL9/10 and CXCL11, MCP-1, MCP-3, and granzyme A.
  • Systemic immune activation was observed after the single administration of CAN-2409, prior to initiation of nivolumab (week 3 post treatment).
  • The data support the potential therapeutic synergies between CAN-2409 in combination with immune checkpoint inhibitors across various solid tumors.

AIM ImmunoTech Announces Abstract Entitled, Negative Impact of Paclitaxel on Human Breast Tumor Microenvironment and Its Reversal by the Combination of Interferon-α with TLR3 Agonist Rintatolimod, (Ampligen®), Accepted for Poster Presentation by Roswell

Retrieved on: 
Thursday, March 24, 2022
Private Securities Litigation Reform Act, Company, Cancer, PSLRA, Therapy, Date, Roswell Park Comprehensive Cancer Center, CCL5, TME, NYSE, PCR, CXCL8, CXCL10, Tumor microenvironment, AACR, Research, Doctor of Philosophy, Breast, CDT, American Association, Probability, CXCL9, Tissue, Rintatolimod, ELISA, Chemokine, American, Immunology, Association, American Association for Cancer Research, Paclitaxel, Taxane, Macrophage, CXCL11, TLR3, TaqMan, COVID-19, CTL, GLOBE, Breast cancer, Degenerative disease, CKM, Time, Lists of diseases, NK, CCL22, Patient, Disease, AIM, Medical imaging, Vaccine, MD

Our current data highlight thepotential for the chemokine modulatory regimen to enhance the effectiveness of taxane-based chemotherapy of breast cancer and potentially other diseases.

Key Points: 
  • Our current data highlight thepotential for the chemokine modulatory regimen to enhance the effectiveness of taxane-based chemotherapy of breast cancer and potentially other diseases.
  • Unexpectedly, paclitaxel treatment resulted in further elevation of granulocyte/MDSC-attractant CXCL8 and CCL22, which was reversed by the combination of paclitaxel with the CKM including Ampligen.
  • Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA.
  • The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

AIM ImmunoTech Announces Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the AACR 2022 Annual Meeting

Retrieved on: 
Wednesday, March 9, 2022
Online, MSD, UPMC Hillman Cancer Center, Rintatolimod, Tumor necrosis factor, Biomarker, AACR, American Association for Cancer Research, Trial of the century, University, AIM, Research, Therapy, Phase II, Survival, IV, Date, American, TNF, Degenerative disease, University of Pittsburgh Medical Center, MD, Lists of diseases, Perforin, Wilfrid Sellars, Cancer, Ovarian cancer, NYSE, GLOBE, CXCL11, Patient, American Association, CXCL10, COVID-19, IVP, Disease, Time, Association, IP, Cisplatin, CXCL9, Pharmaceutical industry

The clinical trials abstract titles and text are now available on the AACR Online itinerary planner .

Key Points: 
  • The clinical trials abstract titles and text are now available on the AACR Online itinerary planner .
  • A total of 17 patients were enrolled and 13 were evaluable for response in the ongoing Phase 2 trial.
  • Peritoneal fluid aspiration (IP wash) was performed in 13 patients at multiple time points during each cycle of treatment.
  • Washes were collected on Days 1-3 of each cycle, before and after each treatment.